drugset / Trial / NCT00006099
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
Phase 1
Terminated
1 enrolled
Ludwig Institute for Cancer Research
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelDiagnostic
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Giving monoclonal antibodies in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have ovarian cancer.
Timeline
- Start
- 2000-08-02
- Primary completion
- 2002-02-26
- Completion
- 2002-08-12
Outcome
Outcome not reported
Stopped (Enrollment): “low study accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hu3S193 | Monoclonal antibody | 5 mg | Other |